Научно-практическая ревматология

Расширенный поиск


Полный текст:

Список литературы

1. <div><p>Smolen J., Aletaha D., Bijlsma J. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.</p><p>Verstappen S.M.M., Bijlsma J.W., Verkleij H. et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthr Rheum 2004; 51: 488-97.</p><p>Wolfe F., Michaud K., Choi H.K., Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol 2005; 32(10): 1875—83.</p><p>Mau W., Listing J., Huscher D. et al. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 2005; 32: 721-8.</p><p>Horton S.C., Das S., Emery P. Certolizumab pegol in rheumatoid arthritis: a review of phase III clinical trials and its role in real-life clinical practice. Int J Clin Rheum 2011; 5(5): 517-27.</p><p>Buch M.H., Bingham S.J., Bryer D., Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology 2007; 46(7): 1153-6.</p><p>Buch M.H., Vital E.M., Dass S. et al. Switching to rituximab and an alternative inhibitor in patients with rheumatoid arthritis that have failed previous TNF inhibitor are both effective treatment options with good maintenance rates (abstract). Ann Rheum Dis 2010; 69(Suppl. 3): 379.</p><p>Smolen J.S., Kay J., Doyle M.K. et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374(9685): 210—21.</p><p>Buch M.H., Conaghan P.G., Quinn M.A. et al. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin a? Ann Rheum Dis 2004; 63(10): 1344-6.</p><p>Насонов Е.Л. Эффективность и безопасность ингибиторов фактора некроза опухоли α при ревматоидном артрите. Рус. мед. журн. 2008; 16(24): 1602—9.</p><p>Verstappen S.M.M., Watson K.D., Lunt M. et al. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49(8): 1570-7.</p><p>Lamour S., Bracher M., Nesbitt A. The PEG component of certolizumab pegol inhibits degranulation by stimulated mast cells (abstract). Arthr Rheum 2009; 60(Suppl. 10): 44.</p><p>Fossati G., Nesbitt A. Certolizumab pegol has a different profile from the other anti-TNFs, including golimumab, in a variety of in vitro assays (abstract). Ann Rheum Dis 2010; 69(Suppl. 3): 324</p><p>Furst D.E., Schiff M.H., Fleischmann R.M. et al. Adalimumab, a fully human anti tumor necrosis factor a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30(12): 2563—71.</p><p>Porter C., Kopotsha T., Smith B. et al. No significant transfer of certolizumab pegol compared with IgG in the perfused human placenta in vitro (abstract). Ann Rheum Dis 2010; 69(Suppl. 3): 210.</p><p>Wolf D., Mahadevan U. Certolizumab pegol use in pregnancy: low levels detected in cord blood (abstract). Arthr Rheum 2010; 62(Suppl. 10): 299.</p><p>Keystone E., van der Heijde D., Mason D. et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthr Rheum 2008; 58: 3319-29.</p><p>Smolen J.S., Landewe R., Mease P. et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.</p><p>Smolen J.S., van Vollenhoven R.F., Kavanaugh A. et al. Efficacy and safety of certolizumab pegol plus methotrexate in patients with rheumatoid arthritis: 3-year data from the RAPID2 study. Ann Rheum Dis 2010; 69 (Suppl. 3): 528.</p><p>Fleischmann R. The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact of quality of life. Open Access Rheum Res Rev 2009; 1: 95-105</p><p>Fleischmann R., Vencovsky J., van Vollenhoven R. et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805-11.</p><p>Osterhause J.T., Purcaru O., Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis specific work productivity survey (WPS0RA). Arthr Res Ther 2009; 11: R73.</p><p>Hazes J.M., Tailor P., Strand V. et al. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology 2010; 49(10): 1900-10.</p><p>Strand V., Mease P., Burmester G. et al. Rapid and sustained improvement in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomised controlled trial. Arthr Res Ther 2009; 11(6): R170.</p></div><br />

Для цитирования:

Amirdjanova V.N., Pogozheva E.Y. КАЧЕСТВО ЖИЗНИ БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ, ПОЛУЧАЮЩИХ ЦЕРТУЛИЗУМАБА ПЭГОЛ. Научно-практическая ревматология. 2012;50(5):80-84.

For citation:

Amirdjanova V.N., Pogozheva E.Yu. QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL. Rheumatology Science and Practice. 2012;50(5):80-84. (In Russ.)

Просмотров: 717

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)